Stocklytics Platform
Asset logo for symbol ASRT
Assertio Therapeutics
ASRT69
$0.69arrow_drop_down1.45%-$0.01
Penny Stock
Asset logo for symbol ASRT
ASRT69

$0.69

arrow_drop_down1.45%

Income Statement (ASRT)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$2.11M-$2.76M-$3.61M-$31.15M-$3.82M
EBITDA$4.59M$3.94M$2.11M-$26.24M$6.55M
gross Profit$21.65M$22.23M$15.54M$18.35M$28.56M
NET Income-$2.92M-$3.67M-$4.51M-$57.38M-$279.54M
total Revenue$29.20M$31.12M$32.44M$32.98M$35.62M

Balance Sheet (ASRT)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt$1.73M-$4.08M-$39.97M-$32.52M-$38.02M
stockholders Equity$130.51M$132.15M$134.49M$138.00M$192.87M
total Assets$275.99M$279.44M$281.96M$286.41M$380.02M
total Debt$39.71M$40.64M$40.76M$40.91M$38.86M
total Liabilities$145.48M$147.29M$147.47M$148.41M$187.15M

Cash Flow (ASRT)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow-$10.00K-$75.00K-$206.00K-$8.91M-$10.00K
free Cash Flow-$35.00K$7.38M$7.50M$5.88M$2.57M
investing Cash Flow-----
operating Cash Flow-$35.00K$7.38M$7.50M$5.70M$2.57M

Assertio Therapeutics (ASRT) Financials

Assertio Therapeutics Inc (ASRT) provides an overview of its financials through its income statement, EBIT (Earnings Before Interest and Taxes), EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), gross profit, net income from stockholders, total revenue, balance sheet, cash equivalents, net debt, stockholders equity, total assets, total debt, total liabilities, cash flow, financing cash flow, free cash flow, investing cash flow, and operating cash flow. These financial metrics allow investors and stakeholders to assess the company's performance and financial health.
The income statement reflects Assertio Therapeutics Inc's revenue and expenses over a specific period. It provides insights into the company's net income, gross profit, and operating expenses. EBIT represents the company's earnings before deducting interest and taxes, providing a measure of its operating performance. EBITDA goes further by excluding depreciation and amortization expenses, giving a clearer picture of the company's profitability.
Gross profit is the revenue generated by the company after deducting the cost of goods sold. It indicates the company's ability to generate profits from its core operations. Net income from stockholders represents the portion of net income attributable to the company's stockholders.
Total revenue is the sum of all revenue generated by the company, including sales of products and services. The balance sheet provides a snapshot of the company's financial position, showing its assets, liabilities, and stockholders' equity. Cash equivalents refer to highly liquid and short-term investments that can be readily converted into cash.
Net debt is the company's total debt minus its cash and cash equivalents. Stockholders' equity represents the residual interest in the assets of the company after deducting its liabilities. Total assets encompass all the resources owned by the company.
Total debt refers to the company's obligations, including both short-term and long-term debt. Total liabilities include the company's debts, obligations, and other liabilities.
Cash flow represents the movement of cash into and out of the company. Financing cash flow shows the cash generated or expended from financing activities, such as issuing or repurchasing stock and borrowing or repaying debt. Free cash flow measures the cash generated by the company's operations after deducting capital expenditures.
Investing cash flow reflects the cash used for or generated from investing activities, such as purchasing or selling assets. Operating cash flow shows the cash generated by the company's day-to-day operations, excluding investing and financing activities.
add Assertio Therapeutics  to watchlist

Keep an eye on Assertio Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level